Rosen Law Firm reminded investors of a filed securities class action involving Capricor Therapeutics, Inc., whose securities were purchased between Dec. 17, 2025, and July 26, 2026. Investors seeking to serve as lead plaintiff must move the Court by Sept. 28, 2026. The lawsuit alleges Capricor changed its pre-specified statistical analysis plan for Deramiocel clinical data without FDA agreement before resubmitting its Biologics License Application, creating a substantial risk to approval of the cell therapy for Duchenne muscular dystrophy. No class has been certified.